Need Help?

Genomic characterization of Malignant Pleural Mesothelioma.

Genomic characterization of Malignant Pleural Mesothelioma using RNA-seq, Exome and Illumina 2.5 M array.

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

5 Datasets 18 Publications

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001001913	Exome sequencing data for Mesothelioma	Illumina HiSeq 2500	198
EGAD00001001914	RNA-seq data for mesothelioma cell lines after spliceostatin (SSA) or control (DMSO) treatment.	Illumina HiSeq 2000	12
EGAD00001001915	RNA-Seq data for Mesothelioma.	Illumina HiSeq 2000	211
EGAD00001001916	Targeted sequencing using SPET for Mesothelioma.	Illumina HiSeq 2000	207
EGAD00001001917	PacBio data for mesothelioma cell line NCI-H2595.	PacBio RS II	1

Publications	Citations
Genomics and Epigenetics of Malignant Mesothelioma. Sage AP, Martinez VD, Minatel BC, Pewarchuk ME, Marshall EA, MacAulay GM, Hubaux R, Pearson DD, Goodarzi AA, Dellaire G, Lam WL. High Throughput 7: 2018 E20	24
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, de Koning L, Copin MC, Hofman P, Hofman V, Porte H, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, de Reyniès A, Jean D. Nat Commun 10: 2019 1333	89
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C, Hofman V, Hofman P, Mouroux J, Thomas de Montpreville V, Clermont-Taranchon E, Mazieres J, Rouquette I, Begueret H, Blay JY, Lantuejoul S, Bueno R, Caux C, Girard N, McKay JD, Foll M, Galateau-Salle F, Fernandez-Cuesta L. EBioMedicine 48: 2019 191-202	42
Integrated genomics point to immune vulnerabilities in pleural mesothelioma. Nastase A, Mandal A, Lu SK, Anbunathan H, Morris-Rosendahl D, Zhang YZ, Sun XM, Gennatas S, Rintoul RC, Edwards M, Bowman A, Chernova T, Benepal T, Lim E, Taylor AN, Nicholson AG, Popat S, Willis AE, MacFarlane M, Lathrop M, Bowcock AM, Moffatt MF, Cookson WOCM. Sci Rep 11: 2021 19138	12
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma. Nguyen TT, Lee HS, Burt BM, Amos CI, Cheng C. Br J Cancer 127: 2022 1691-1700	2
Artificial Intelligence Techniques to Predict the Airway Disorders Illness: A Systematic Review. Koul A, Bawa RK, Kumar Y. Arch Comput Methods Eng 30: 2023 831-864	7
Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment. Hariharan A, Qi W, Rehrauer H, Wu L, Ronner M, Wipplinger M, Kresoja-Rakic J, Sun S, Oton-Gonzalez L, Sculco M, Serre-Beinier V, Meiller C, Blanquart C, Fonteneau JF, Vrugt B, Rüschoff JH, Opitz I, Jean D, de Perrot M, Felley-Bosco E. Mol Oncol 16: 2022 3949-3974	2
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Paternot S, Raspé E, Meiller C, Tarabichi M, Assié JB, Libert F, Remmelink M, Bisteau X, Pauwels P, Blum Y, Le Stang N, Tabone-Eglinger S, Galateau-Sallé F, Blanquart C, Van Meerbeeck JP, Berghmans T, Jean D, Roger PP. Mol Oncol 18: 2024 866-894	4
Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau JF, Jean D, Felley-Bosco E. JTO Clin Res Rep 3: 2022 100430	3
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck S, Amos CI, Ripley RT, Burt BM. Clin Cancer Res 29: 2023 548-559	9
Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Pandey GK, Landman N, Neikes HK, Hulsman D, Lieftink C, Beijersbergen R, Kolluri KK, Janes SM, Vermeulen M, Badhai J, van Lohuizen M. Cell Rep Med 4: 2023 100915	6
YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations. Cunningham R, Jia S, Purohit K, Salem O, Hui NS, Lin Y, Carragher NO, Hansen CG. Clin Transl Med 13: 2023 e1190	1
The Pattern of RNA Editing Changes in Pleural Mesothelioma upon Epithelial-Mesenchymal Transition. Felley-Bosco E, Qi W, Jean D, Meiller C, Rehrauer H. Int J Mol Sci 24: 2023 2874	0
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, Bergstrom EN, Kim J, Liu X, Blazquez-Encinas R, Giacobi C, Le Stang N, Boyault S, Cuenin C, Tabone-Eglinger S, Damiola F, Voegele C, Ardin M, Michallet MC, Soudade L, Delhomme TM, Poret A, Brevet M, Copin MC, Giusiano-Courcambeck S, Damotte D, Girard C, Hofman V, Hofman P, Mouroux J, Cohen C, Lacomme S, Mazieres J, de Montpreville VT, Perrin C, Planchard G, Rousseau N, Rouquette I, Sagan C, Scherpereel A, Thivolet F, Vignaud JM, Jean D, Ilg AGS, Olaso R, Meyer V, Boland-Auge A, Deleuze JF, Altmuller J, Nuernberg P, Ibáñez-Costa A, Castaño JP, Lantuejoul S, Ghantous A, Maussion C, Courtiol P, Hernandez-Vargas H, Caux C, Girard N, Lopez-Bigas N, Alexandrov LB, Galateau-Salle F, Foll M, Fernandez-Cuesta L. Nat Genet 55: 2023 607-618	16
A Novel Two-Gene Expression-Based Prognostic Score in Malignant Pleural Mesothelioma. Shivarov V, Blazhev G, Yordanov A. Diagnostics (Basel) 13: 2023 1556	0
Clonal gene signatures predict prognosis in mesothelioma and lung adenocarcinoma. Lin Y, Burt BM, Lee HS, Nguyen TT, Jang HJ, Lee C, Hong W, Ripley RT, Amos CI, Cheng C. NPJ Precis Oncol 8: 2024 47	1
The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop. Fisher SA, Patrick K, Hoang T, Marcq E, Behrouzfar K, Young S, Miller TJ, Robinson BWS, Bueno R, Nowak AK, Lesterhuis WJ, Morahan G, Lake RA. Front Toxicol 6: 2024 1373003	0
BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma. Bisceglia L, Morani F, Guerrieri L, Santoni-Rugiu E, Çakılkaya P, Scatena C, Scarpitta R, Engelholm LH, Behrendt N, Gemignani F, Landi S. Cancer Gene Ther None: 2024 None	0